SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

WorldFinancial

World Liberty Financial (WLFI) is a focal point of discussion due to a congressional probe into its $500 million investment with an Abu Dhabi entity and its ongoing application for a National Trust Bank Charter. This has sparked intense debate, with some community members forecasting substantial growth from its forthcoming real-world asset platform and app, while others strongly denounce it as a fraudulent scheme.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as record Super Bowl betting volume is anticipated, with community discussion intensely focused on how burgeoning prediction markets, operating under different regulatory frameworks, will impact its future profitability and market share amidst its own expansion into the evolving sector ahead of its impending earnings report.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending after its swift decision to cease offering a compounded weight-loss pill following regulatory scrutiny and legal threats from major pharmaceutical companies. The community is divided, with some viewing it as a strategic de-risking move for its core telehealth business, while others criticize it as a major management blunder that damages trust and growth, amidst mixed reactions to its Super Bowl advertisement.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending due to widespread discussions surrounding a potential future merger involving SpaceX and xAI, alongside recent announcements about high-volume Semi production and significant investments in AI, robotics, and autonomous driving. This is fueling bullish outlooks for its long-term vision, though the community also expresses concerns about near-term profitability and ongoing controversies related to its CEO.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending amid a federal probe into alleged workplace discrimination and high anticipation for a Supreme Court ruling on tariffs that could impact its margins. While some in the community are betting on a strategic turnaround driven by new product innovation and North American growth, others remain skeptical, citing continued weakness in key markets.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is trending following its recent acquisition and new financing designed to strengthen its HAE portfolio, yet community discussion remains largely negative, citing persistent stock undervaluation, increasing short interest, and perceived manipulation, further fueled by public comments from well-known financial personalities.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending following a recently announced $250 million financing amendment that extends its capital runway through 2028, fueling community speculation about a potential short squeeze and comparisons to its history of massive parabolic price movements. While many anticipate significant upward momentum, a notable counter-narrative raises concerns about potential dilution from the equity line of credit and the company's underlying profitability.

Block, Inc. engages in creating ecosystems for distinct customer audiences. It operates through the Square and Cash App segments. The Square segment provides payment services, software solutions, hardware, and financial services to sellers. The Cash App segment includes the financial tools available to individuals within the mobile Cash App, including peer-to-peer payments, bitcoin and stock investments. It also includes Cash App Card, which is linked to customer stored balances that customers can use to pay for purchases or withdraw funds from an ATM. The company was founded by Jack Patrick Dorsey and James Morgan McKelvey in February 2009 and is headquartered in Oakland, CA.

Block Inc - Ordinary Shares - Class A

Block Inc

Block Inc. is trending as reports surface about significant workforce reductions affecting up to 10% of its staff, coupled with cautious Q4 growth outlooks for its Square segment. The news fuels community discussions comparing its strategic efficiency moves and leadership's Bitcoin focus against the backdrop of broader fintech sector challenges.

Syntec Optics Holdings, Inc. engages in the design and manufacture of optics and photonics enabled products. The company was founded in 1981 and is headquartered in Rochester, NY.

Syntec Optics Holdings Inc. - Ordinary Shares - Class A

Syntec Optics Holdings Inc

Syntec Optics (OPTX) is gaining significant attention due to its critical role in cutting-edge defense contracts for AR systems like Anduril's EagleEye and surging demand for its space and AI infrastructure optics, with community discussion highlighting its exceptionally tight float and strong insider ownership as key bullish factors.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors eagerly await its BLA resubmission in February, a key step validated by the FDA's request for the full HOPE-3 clinical study report without additional trials. This development reinforces confidence in its Duchenne muscular dystrophy therapy and promising exosome platform amidst discussions of institutional interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sanofi Invests $18.96 Million in Immuneering Corporation $IMRX

Sanofi bought a new stake in shares of Immuneering Corporation (NASDAQ:IMRX - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The...

Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seven research firms that are currently covering the firm, Marketbeat reports...

Immuneering (NASDAQ:IMRX) Insider Purchases $24,990.00 in Stock

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) insider Harold Eugene Brakewood purchased 5,250 shares of the business's stock in a transaction dated Friday, January 16th. The shares were...

Immuneering (NASDAQ:IMRX) Insider Harold Eugene Brakewood Purchases 5,250 Shares of Stock

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) insider Harold Eugene Brakewood purchased 5,250 shares of Immuneering stock in a transaction dated Friday, January 16th. The shares were...

Thomas Schall Purchases 21,645 Shares of Immuneering (NASDAQ:IMRX) Stock

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) Director Thomas Schall bought 21,645 shares of the business's stock in a transaction that occurred on Thursday, January 15th. The shares were...

Immuneering Corporation (NASDAQ:IMRX) Sees Significant Growth in Short Interest

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) saw a large growth in short interest in December. As of December 31st, there was short interest totaling 10,924,303 shares, a growth of 43.1...

Immuneering (NASDAQ:IMRX) Insider Acquires $10,501.86 in Stock

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) insider Brett Matthew Hall acquired 2,298 shares of the stock in a transaction that occurred on Thursday, January 15th. The shares were bought...

Insider Buying: Immuneering (NASDAQ:IMRX) Insider Purchases 2,298 Shares of Stock

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) insider Brett Matthew Hall purchased 2,298 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was...

Immuneering (NASDAQ:IMRX) Insider Purchases $10,897.90 in Stock

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) insider Leah Neufeld bought 2,626 shares of Immuneering stock in a transaction on Tuesday, January 13th. The shares were acquired at an average...

Immuneering (NASDAQ:IMRX) Insider Acquires $10,897.90 in Stock

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) insider Leah Neufeld bought 2,626 shares of Immuneering stock in a transaction dated Tuesday, January 13th. The shares were acquired at an...

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corp - Ordinary Shares Class A

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

Current Price	$4.93
Prev Close	$4.52
Open	$4.62
Dividend Yield	0.00%
50-Day Moving Average	$5.81
Beta	1.32
Avg. Volume	3.01M
PE Ratio	-2.76

52-Week High	$10.08
52-Week Low	$1.10
Market Capitalization	$318.33M
EPS (Annual)	-$2.04
Price to Book	1.37
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

IMRX
Immuneering Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IMRX News

IMRXImmuneering Corp